AN2 Therapeutics Names Dr. Cameron Trenor as Chief Medical Officer

AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics, has appointed Cameron Trenor, M.D., as Chief Medical Officer.

Trenor is a physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He has played key leadership roles in advancing novel therapeutics from discovery and translational research through global clinical development, regulatory interactions and commercialization planning.

“We are delighted to welcome Cameron to AN2 Therapeutics,” said Eric Easom, Co-Founder, President and CEO of AN2 Therapeutics. “Cameron’s extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline. His scientific rigor, patient-centric mindset and proven leadership across both emerging biotechnology companies and large pharmaceutical organizations make him an outstanding addition to our executive team.”

Experience

Most recently, Trenor served as Chief Medical Officer of Cellarity, where he led the establishment of its medical organization through its transition to a clinical-stage biotechnology company. As Chief Medical Officer, he oversaw development of Cellarity’s lead program, including the company’s first IND submission and initiation of a global first-in-human clinical study.

Prior to Cellarity, Trenor served as Executive Medical Director at Forma Therapeutics, which was acquired by Novo Nordisk, where he led global clinical development activities for etavopivat across multiple indications and supported the program’s advancement from early clinical development into Phase 3. Earlier in his career, he led clinical and translational programs in hematology and rare diseases at Novartis Institutes for BioMedical Research.

He remains a practicing pediatric hematologist-oncologist at Boston Children’s Hospital and has authored approximately 60 peer-reviewed research publications. Trenor received a B.S. in Biology from Tufts University, an M.D. from the University of Tennessee College of Medicine and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. He completed his residency and fellowship training through Boston Children’s Hospital, Boston Medical Center and Dana-Farber Cancer Institute and is board-certified in Pediatric Hematology-Oncology.